Biote Corp. Announces Leadership Transition to Enhance Growth and Preventive Healthcare

Biote Corp. Announces Leadership Transition to Drive Future Growth

Biote Corp., a leader in preventive healthcare through hormone optimization and therapeutic wellness, is set to undergo a significant leadership transition. Terry Weber, the current Chief Executive Officer, announces her retirement effective February 1, 2025, after six years of dedicated service. During her tenure, Biote has expanded to over 7,000 certified practitioners, focusing primarily on enhancing patient health, especially in women's health. Weber's leadership has been instrumental in fostering a culture of change within the company, empowering practitioners to engage in transformative healthcare conversations. She transitions to a role as Strategic Advisor, aiming to continue contributing to Biote's mission even after stepping down.

Bret Christensen, who takes the reins as CEO and Director on the same date, brings over 20 years of extensive experience in the healthcare industry, particularly in women’s health. His previous roles at Hologic, Myriad Genetics, and Insulet highlight a strong track record of driving advancements in medical treatments. Marc Beer, Executive Chairman of Biote, expresses confidence in Christensen's ability to lead the company into its next growth phase. Beer emphasizes Christensen's deep understanding of the healthcare landscape, suggesting that his leadership could significantly enhance Biote’s initiatives in hormone optimization and therapeutic wellness.

The timing of this leadership change aligns with Biote's strategic goals of expanding its reach and effectiveness in the evolving healthcare marketplace. Christensen's commitment to exploring new growth opportunities indicates a proactive approach to navigating industry challenges and leveraging Biote's established foundations. This transition not only marks a new chapter for the company but also reflects its dedication to improving patient outcomes through innovative healthcare solutions.

In addition to the leadership changes, Biote continues to focus on its core mission of preventive healthcare. The company aims to enhance its offerings in hormone optimization while addressing broader therapeutic wellness needs. As the healthcare landscape evolves, Biote remains committed to its vision of empowering practitioners and patients alike through personalized healthcare solutions that can lead to better overall health outcomes.

This leadership transition signifies a pivotal moment for Biote, setting the stage for continued growth and value creation in a rapidly changing industry. The expertise that Christensen brings may well position Biote at the forefront of preventive healthcare innovations, solidifying its role as a leader in personalized wellness.